Low level of TERC gene amplification between chronic myeloid leukaemia patients resistant and respond to imatinib mesylate treatment

Zaidatul Shakila Mohamad Ashari, Sarina Sulong, Rosline Hassan, Azlan Husin, Goh Ai Sim, S Fadilah S. Abdul Wahid

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The amplification of telomerase component (TERC) gene could play an important role in generation and treatment of haematological malignancies. This present study was aimed to investigate copy number amplification status of TERC gene in chronic myeloid leukaemia (CML) patients who were being treated with imatinib mesylate (IM). Genomic DNA was extracted from peripheral blood of CML-IM Resistant (n=63), CML-IM Respond (n=63) and healthy individuals (n=30). TERC gene copy number predicted (CNP) and copy number calculated (CNC) were determined based on Taqman® Copy Number Assay. Fluorescence in situ hybridization (FISH) analysis was performed to confirm the normal signal pattern in C4 (calibrator) for TERC gene. Nine of CML patients showed TERC gene amplification (CNP=3), others had 2 CNP. A total of 17 CML patients expressed CNC>2.31 and the rest had 2.31>CNC>1.5. TERC gene CNP value in healthy individuals was 2 and their CNC value showed in range 1.59-2.31. The average CNC TERC gene copy number was 2.07, 1.99 and 1.94 in CML-IM Resistant patients, CML-IM Respond and healthy groups, respectively. No significant difference of TERC gene amplification observed between CML-IM Resistant and CML-IM Respond patients. Low levels of TERC gene amplification might not have a huge impact in haematological disorders especially in terms of resistance towards IM treatment.

Original languageEnglish
Pages (from-to)1863-1869
Number of pages7
JournalAsian Pacific Journal of Cancer Prevention
Volume15
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

Gene Amplification
Telomerase
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Gene Dosage
Gene Components
Therapeutics
Imatinib Mesylate
Hematologic Neoplasms
Fluorescence In Situ Hybridization
DNA

Keywords

  • CML
  • Gene amplification
  • Imatinib mesylate resistance
  • Telomerase RNA component

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Public Health, Environmental and Occupational Health
  • Epidemiology

Cite this

Low level of TERC gene amplification between chronic myeloid leukaemia patients resistant and respond to imatinib mesylate treatment. / Ashari, Zaidatul Shakila Mohamad; Sulong, Sarina; Hassan, Rosline; Husin, Azlan; Sim, Goh Ai; S. Abdul Wahid, S Fadilah.

In: Asian Pacific Journal of Cancer Prevention, Vol. 15, No. 4, 2014, p. 1863-1869.

Research output: Contribution to journalArticle

Ashari, Zaidatul Shakila Mohamad ; Sulong, Sarina ; Hassan, Rosline ; Husin, Azlan ; Sim, Goh Ai ; S. Abdul Wahid, S Fadilah. / Low level of TERC gene amplification between chronic myeloid leukaemia patients resistant and respond to imatinib mesylate treatment. In: Asian Pacific Journal of Cancer Prevention. 2014 ; Vol. 15, No. 4. pp. 1863-1869.
@article{336e3376b98d45dba5db7c58c3aaedc3,
title = "Low level of TERC gene amplification between chronic myeloid leukaemia patients resistant and respond to imatinib mesylate treatment",
abstract = "The amplification of telomerase component (TERC) gene could play an important role in generation and treatment of haematological malignancies. This present study was aimed to investigate copy number amplification status of TERC gene in chronic myeloid leukaemia (CML) patients who were being treated with imatinib mesylate (IM). Genomic DNA was extracted from peripheral blood of CML-IM Resistant (n=63), CML-IM Respond (n=63) and healthy individuals (n=30). TERC gene copy number predicted (CNP) and copy number calculated (CNC) were determined based on Taqman{\circledR} Copy Number Assay. Fluorescence in situ hybridization (FISH) analysis was performed to confirm the normal signal pattern in C4 (calibrator) for TERC gene. Nine of CML patients showed TERC gene amplification (CNP=3), others had 2 CNP. A total of 17 CML patients expressed CNC>2.31 and the rest had 2.31>CNC>1.5. TERC gene CNP value in healthy individuals was 2 and their CNC value showed in range 1.59-2.31. The average CNC TERC gene copy number was 2.07, 1.99 and 1.94 in CML-IM Resistant patients, CML-IM Respond and healthy groups, respectively. No significant difference of TERC gene amplification observed between CML-IM Resistant and CML-IM Respond patients. Low levels of TERC gene amplification might not have a huge impact in haematological disorders especially in terms of resistance towards IM treatment.",
keywords = "CML, Gene amplification, Imatinib mesylate resistance, Telomerase RNA component",
author = "Ashari, {Zaidatul Shakila Mohamad} and Sarina Sulong and Rosline Hassan and Azlan Husin and Sim, {Goh Ai} and {S. Abdul Wahid}, {S Fadilah}",
year = "2014",
doi = "10.7314/APJCP.2014.15.4.1863",
language = "English",
volume = "15",
pages = "1863--1869",
journal = "Asian Pacific Journal of Cancer Prevention",
issn = "1513-7368",
publisher = "Asian Pacific Organization for Cancer Prevention",
number = "4",

}

TY - JOUR

T1 - Low level of TERC gene amplification between chronic myeloid leukaemia patients resistant and respond to imatinib mesylate treatment

AU - Ashari, Zaidatul Shakila Mohamad

AU - Sulong, Sarina

AU - Hassan, Rosline

AU - Husin, Azlan

AU - Sim, Goh Ai

AU - S. Abdul Wahid, S Fadilah

PY - 2014

Y1 - 2014

N2 - The amplification of telomerase component (TERC) gene could play an important role in generation and treatment of haematological malignancies. This present study was aimed to investigate copy number amplification status of TERC gene in chronic myeloid leukaemia (CML) patients who were being treated with imatinib mesylate (IM). Genomic DNA was extracted from peripheral blood of CML-IM Resistant (n=63), CML-IM Respond (n=63) and healthy individuals (n=30). TERC gene copy number predicted (CNP) and copy number calculated (CNC) were determined based on Taqman® Copy Number Assay. Fluorescence in situ hybridization (FISH) analysis was performed to confirm the normal signal pattern in C4 (calibrator) for TERC gene. Nine of CML patients showed TERC gene amplification (CNP=3), others had 2 CNP. A total of 17 CML patients expressed CNC>2.31 and the rest had 2.31>CNC>1.5. TERC gene CNP value in healthy individuals was 2 and their CNC value showed in range 1.59-2.31. The average CNC TERC gene copy number was 2.07, 1.99 and 1.94 in CML-IM Resistant patients, CML-IM Respond and healthy groups, respectively. No significant difference of TERC gene amplification observed between CML-IM Resistant and CML-IM Respond patients. Low levels of TERC gene amplification might not have a huge impact in haematological disorders especially in terms of resistance towards IM treatment.

AB - The amplification of telomerase component (TERC) gene could play an important role in generation and treatment of haematological malignancies. This present study was aimed to investigate copy number amplification status of TERC gene in chronic myeloid leukaemia (CML) patients who were being treated with imatinib mesylate (IM). Genomic DNA was extracted from peripheral blood of CML-IM Resistant (n=63), CML-IM Respond (n=63) and healthy individuals (n=30). TERC gene copy number predicted (CNP) and copy number calculated (CNC) were determined based on Taqman® Copy Number Assay. Fluorescence in situ hybridization (FISH) analysis was performed to confirm the normal signal pattern in C4 (calibrator) for TERC gene. Nine of CML patients showed TERC gene amplification (CNP=3), others had 2 CNP. A total of 17 CML patients expressed CNC>2.31 and the rest had 2.31>CNC>1.5. TERC gene CNP value in healthy individuals was 2 and their CNC value showed in range 1.59-2.31. The average CNC TERC gene copy number was 2.07, 1.99 and 1.94 in CML-IM Resistant patients, CML-IM Respond and healthy groups, respectively. No significant difference of TERC gene amplification observed between CML-IM Resistant and CML-IM Respond patients. Low levels of TERC gene amplification might not have a huge impact in haematological disorders especially in terms of resistance towards IM treatment.

KW - CML

KW - Gene amplification

KW - Imatinib mesylate resistance

KW - Telomerase RNA component

UR - http://www.scopus.com/inward/record.url?scp=84896929538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896929538&partnerID=8YFLogxK

U2 - 10.7314/APJCP.2014.15.4.1863

DO - 10.7314/APJCP.2014.15.4.1863

M3 - Article

C2 - 24641422

AN - SCOPUS:84896929538

VL - 15

SP - 1863

EP - 1869

JO - Asian Pacific Journal of Cancer Prevention

JF - Asian Pacific Journal of Cancer Prevention

SN - 1513-7368

IS - 4

ER -